FrancophonIA/ELRC3.0 huggingface dataset:
English: In a single-dose study in patients with type 2 diabetes, treatment with 300 mg before a mixed meal delayed intestinal glucose absorption and reduced postprandial glucose through both a renal and a non-renal mechanism.
Slovenian: V študiji posameznih odmerkov pri bolnikih s sladkorno boleznijo tipa 2 je odmerek 300 mg pred mešanim obrokom upočasnil absorpcijo glukoze v črevesju in zmanjšal postprandialne vrednosti glukoze tako z ledvičnim kot z neledvičnim mehanizmom.
English: Constipation, Thirst f, Nausea
Slovenian: Bolezni prebavil pogosti obstipacija, žeja f, navzea
English: Due to volume depletion, generally small mean decreases in eGFR were seen within the first 6 weeks of treatment initiation with canagliflozin.
Slovenian: Zaradi hipovolemije so v prvih 6 tednih po začetku zdravljenja s kanagliflozinom opazili večinoma majhno povprečno zmanjšanje eGFR.
English: For patients switching from separate tablets of canagliflozin and metformin, Vokanamet should be initiated at the same total daily dose of canagliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin.
Slovenian: Bolniki, ki prehajajo z uporabe ločenih tablet kanagliflozina in metformina, naj zdravilo Vokanamet začnejo jemati v odmerku, ki vsebuje enaka dnevna odmerka kanagliflozina in metformina, kot so ju že jemali, oziroma najbližji približek terapevtsko ustreznega odmerka metformina.
English: Table 6: Efficacy results from active-controlled clinical studies Compared to glimepiride as dual therapy with metformin (52 weeks) Canagliflozin + metformin Glimepiride (titrated) + metformin (N = 482)
Slovenian: Preglednica 6: Rezultati učinkovitosti iz kliničnih študij nadzorovanih z učinkovino V primerjavi z glimepiridom pri dvotirnem zdravljenju z metforminom (52 tednov) kanagliflozin + metformin glimepirid (s titracijo) + metformin (n = 482)
English: Do not take Vokanamet
Slovenian: Ne jemljite zdravila Vokanamet
English: Mean percent increases from baseline for canagliflozin 100 mg and 300 mg versus placebo, respectively, were total cholesterol 3.4% and 5.2% versus 0.9%; HDL-cholesterol 9.4% and 10.3% versus 4.0%; LDL-cholesterol 5.7% and 9.3% versus 1.3%; non-HDL-cholesterol 2.2% and 4.4% versus 0.7%; triglycerides 2.4% and 0.0% versus 7.6%.
Slovenian: Povprečni odstotek povečanja glede na začetno vrednost za 100 mg kanagliflozina in 300 mg kanagliflozina v primerjavi s placebom je bil za celokupni holesterol 3,4% in 5,2% v primerjavi z 0,9%; HDL-holesterol 9,4% in 10,3% v primerjavi s 4,0%; LDL-holesterol 5,7% in 9,3% v primerjavi z 1,3%; ne-HDL-holesterol 2,2% in 4,4% v primerjavi z 0,7%; trigliceride 2,4% in 0,0% v primerjavi z 7,6%.
English: Canagliflozin has not been studied in severe renal impairment (eGFR < 30 mL/min/1.73 m 2 or CrCl < 30 mL/min) or end-stage renal disease (ESRD).
Slovenian: Kanagliflozina niso preučevali pri hudi okvari ledvic (pri eGFR < 30 ml/min/1,73 m oziroma pri očistku kreatinina < 30 ml/min ) ali končni odpovedi ledvic.
English: This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium free'.
Slovenian: Zdravilo Vokanamet vsebuje natrij To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na tableto, kar v bistvu pomeni ‘brez natrija'.
English: If this happens, you must stop taking Vokanamet and talk to a doctor or go to the nearest hospital immediately, as lactic acidosis may lead to coma.
Slovenian: V tem primeru morate prenehati jemati zdravilo Vokanamet in se takoj posvetovati z zdravnikom ali oditi v najbližjo bolnišnico, saj lahko laktacidoza vodi v komo.
English: The CANVAS Program compared the risk of experiencing a Major Adverse Cardiovascular Event (MACE) defined as the composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke, between canagliflozin and placebo on a background of standard of care treatments for diabetes and atherosclerotic cardiovascular disease.
Slovenian: V programu CANVAS so primerjali tveganje za pojav pomembnega kardiovaskularnega neželenega dogodka (MACE, Major Adverse Cardiovascular Event), ki ga sestavljajo kardiovaskularna smrt, preživetje miokardnega infarkta in preživetje možganske kapi, in sicer so primerjali tveganje pri uporabi kanagliflozina s tveganjem pri uporabi placeba poleg osnovnega zdravljenja v okviru standardne oskrbe pri sladkorni bolezni in aterosklerotični kardiovaskularni bolezni.
English: When canagliflozin/metformin was administered at 60/300 mg/kg/day (exposure levels 11 and 13 times the clinical exposure for canagliflozin and metformin, respectively, at 300/2000 mg doses), the effects were more pronounced compared to metformin alone.
Slovenian: Pri odmerjanju kombinacije kanagliflozin/metformin v odmerku 60/300 mg/kg/dan (pri izpostavljenosti, ki je bila 11-krat oziroma 13-krat večja od klinične izpostavljenosti kanagliflozinu oziroma metforminu pri odmerkih 300/2000 mg) so bili učinki bolj izraženi kot pri uporabi samo metformina.
English: Baseline renal function was normal or mildly impaired in 80% of patients and moderately impaired in 20% of patients (mean eGFR 77 mL/min/1.73 m2).
Slovenian: Ob izhodišču je imelo normalno ali blago zmanjšano ledvično funkcijo 80% bolnikov, zmerno zmanjšano ledvično funkcijo pa 20% bolnikov (s povprečno eGFR 77 ml/min/1,73 m2).
English: For patients switching from separate tablets of canagliflozin and metformin
Slovenian: Bolniki, ki prehajajo z uporabe ločenih tablet kanagliflozina in metformina
English: Tell your doctor as soon as possible if you have any of the following side effects: Hypoglycaemia (very common, may affect more than 1 in 10 people)
Slovenian: Če se pri vas pojavi kateri od naslednjih neželenih učinkov, čimprej obvestite zdravnika: Hipoglikemija (zelo pogosti; pojavijo se lahko pri več kot 1 od 10 bolnikov)
English: Following co-administration of canagliflozin with rifampicin (an inducer of various active transporters and medicinal product-metabolising enzymes), 51% and 28% decreases in canagliflozin systemic exposure (area under the curve, AUC) and peak concentration (Cmax) were observed.
Slovenian: Pri sočasni uporabi kanagliflozina z rifampicinom (ki je induktor številnih aktivnih prenašalcev in encimov, ki presnavljajo zdravila) so opazili zmanjšanje sistemske izpostavljenosti (AUC- Area Under the Curve) kanagliflozinu za 51% in zmanjšanje najvišje plazemske koncentracije (Cmax) za 28%.
English: Patients treated with canagliflozin regardless of baseline eGFR experienced an initial fall in mean eGFR.
Slovenian: Pri bolnikih, zdravljenih s kanagliflozinom, je prišlo do začetnega znižanja povprečne vrednosti eGFR ne glede na izhodiščno vrednost eGFR.
English: Possible signs of dehydration are: feeling light-headed or dizzy passing out (fainting) or feeling dizzy or faint when you stand up very dry or sticky mouth, feeling very thirsty feeling very weak or tired passing little or no urine fast heartbeat.
Slovenian: Znaki dehidracije so lahko: občutek omotice ali vrtoglavice izguba zavesti (omedlevica) ali omotičnost oziroma omedlevica pri vstajanju v stoječ položaj zelo suha ali lepljiva usta, občutek zelo močne žeje občutek izredne šibkosti ali utrujenosti izločanje zelo malo ali sploh nič urina hiter srčni utrip
English: The most commonly reported adverse reactions during treatment were hypoglycaemia in combination with insulin or a sulphonylurea, vulvovaginal candidiasis, urinary tract infection, and polyuria or pollakiuria (i.e., urinary frequency).
Slovenian: Neželeni učinki, o katerih so med zdravljenjem najbolj pogosto poročali, so bili hipoglikemija pri kombinaciji z insulinom ali s sulfonilsečnino, vulvovaginalna kandidoza, okužba sečil in poliurija ali polakisurija (pogosto uriniranje).
English: Table 1: Tabulated list of adverse reactions (MedDRA) from placebo e and active-controlled studies e and from postmarketing experience
Slovenian: Preglednica 1: Preglednica neželenih učinkov (po klasifikaciji MedDRA) iz s placebom a in aktivno nadzorovanih študij a in neželenih učinkov poročanih v obdobju trženja zdravila
English: Multipack containing 180 (3 x 60) film-coated tablets.
Slovenian: Skupno pakiranje vsebuje 180 (3 x 60) filmsko obloženih tablet.
English: Discontinuation of canagliflozin by male patients due to candidal balanitis or balanoposthitis occurred at a rate of 0.37 events per 100 patient-years.
Slovenian: Do prekinitve zdravljenja s kanagliflozinom zaradi kandidoznega balanitisa ali balanopostitisa je pri bolnikih moškega spola prišlo pri 0,37 dogodkih na 100 bolnikov-let.
English: • if you have signs of a genital yeast infection such as irritation, itching, unusual discharge or odour
Slovenian: • če imate znake genitalne glivične okužbe, kot so vnetje, srbenje, neobičajen izcedek ali vonj.
English: Pharmacotherapeutic group: Drugs used in diabetes, combinations of blood glucose lowering drugs.
Slovenian: Farmakoterapevtska skupina: zdravila za zdravljenje diabetesa, kombinacije antidiabetikov.
English: Balanitis or balanoposthitis includes the terms balanitis, balanoposthitis, balanitis candida, and genital infection fungal.
Slovenian: Izraza balanitis in balanopostitis vključujeta balanitis, balanopostitis, kandidozni balanitis in genitalno glivično okužbo.
English: Canagliflozin reduced the risk for heart failure requiring hospitalization compared to placebo (HR: 0.67; 95% CI (0.52, 0.87)).
Slovenian: Kanagliflozin je v primerjavi s placebom zmanjšal tveganje za srčno popuščanje, zaradi katerega je potreben sprejem v bolnišnico (razmerje ogroženosti: 0,67; 95-odstotni IZ (0,52, 0,87)).
English: • and delay of intestinal glucose absorption.
Slovenian: • in upočasni absorpcijo glukoze v črevesju.
English: Vokanamet is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise:
Slovenian: Zdravilo Vokanamet je indicirano pri odraslih s sladkorno boleznijo tipa 2 kot dodatno zdravljenje ob ustrezni dieti in telesni dejavnosti:
English: In addition to the studies presented above, glycaemic efficacy results observed in an 18-week dual therapy sub-study with a sulphonylurea and a 26-week triple therapy study with metformin and pioglitazone were generally comparable with those observed in other studies.
Slovenian: Poleg zgoraj prikazanih študij so izvedli še 18-tedensko podštudijo z dvotirnim zdravljenjem s sulfonilsečnino in 26-tedensko študijo s trotirnim zdravljenjem z metforminom in pioglitazonom, katerih rezultati glede učinkovitosti zdravila pri urejanju glikemije so večinoma primerljivi z rezultati drugih študij.
English: Compared to healthy subjects, plasma AUC of canagliflozin was increased by approximately 17%, 63%, and 50% in subjects with mild, moderate, and severe renal impairment, respectively, but was similar for ESRD subjects and healthy subjects.
Slovenian: Pri bolnikih z blago, z zmerno oziroma s hudo okvaro ledvic je bila AUC kanagliflozina v plazmi povečana za približno 17%, 63% oziroma 50% v primerjavi z zdravimi osebami, AUC bolnikov s končno ledvično odpovedjo pa je bila podobna AUC pri zdravih osebah.
English: Table 3 presents adverse reactions by SOC and by frequency category reported in patients who received metformin as monotherapy and that were not observed in patients receiving canagliflozin.
Slovenian: V preglednici 3 so po organskih sistemih in po kategoriji pogostnosti navedeni neželeni učinki, o katerih so poročali pri bolnikih, ki so prejemali metformin samostojno, niso pa teh neželenih učinkov opažali pri bolnikih, ki so prejemali kanagliflozin.
English: The higher doses of canagliflozin (100 mg/kg) in male and female rats increased the incidence of pheochromocytomas and renal tubular tumours.
Slovenian: Višji odmerki kanagliflozina (100 mg/kg) so pri podganjih samcih in samicah povečali pogostnost feokromocitoma in tumorjev ledvičnih tubulov.
English: There was no change in metformin AUC; however, mean peak plasma concentration of metformin was decreased by 16% when administered with food.
Slovenian: Pri odmerjanju skupaj s hrano se AUC metformina ni sprememnila, povprečna najvišja koncentracija metformina pa se je znižala za 16%.
English: Results for the 100 mg and 300 mg canagliflozin doses were consistent with results for the combined dose groups.
Slovenian: Rezultati pri uporabi odmerka 100 mg in pri uporabi odmerka 300 mg kanagliflozina se ujemajo z rezultati pri skupinah bolnikov s kombinacijo obeh odmerkov.
English: In a pooled analysis of clinical data, increases in canagliflozin AUC of 26% were observed in UGT1A9*1/*3 carriers and 18% in
Slovenian: Pri analizi združenih kliničnih podatkov so opazili povečanja v AUC kanagliflozina pri nosilcih UGT1A9*1/*3 za 26% in pri nosilcih UGT2B4*2/*2 za 18%.
English: Figure 2: Treatment effect for the primary composite endpoint and its components
Slovenian: Slika 2: Učinek zdravljenja na primarni sestavljeni opazovani dogodek in na posamezne neželene dogodke, ki ga sestavljajo
English: Vokanamet is contraindicated in patients with hepatic impairment due to the active substance metformin (see sections 4.3 and 5.2).
Slovenian: Pri bolnikih z okvaro jeter je uporaba zdravila Vokanamet kontraindicirana, ker zdravilo vsebuje zdravilno učinkovino metformin (glejte poglavji 4.3 in 5.2).
English: Incidence rate (per 100 subject-years) 0.34 HR (95% CI) vs. placebo Minor amputation, n (%) Major amputation, n (%)
Slovenian: celokupno število preiskovancev z dogodki, n (%) incidenčna stopnja (na 100 preiskovancev-let) razmerje ogroženosti (95-odstotni IZ) za primerjavo s placebom manjša amputacija, n (%) večja amputacija, n (%)
English: The effect of canagliflozin on cardiovascular events in adults with type 2 diabetes who had established cardiovascular (CV) disease or were at risk for CVD (two or more CV risk factors), was evaluated in the CANVAS Program (integrated analysis of the CANVAS and the CANVAS-R study).
Slovenian: Učinek kanagliflozina na pojav kardiovaskularnih dogodkov pri odraslih s sladkorno boleznijo tipa 2 in z ugotovljeno kardiovaskularno boleznijo ali s povečanim tveganjem za razvoj kardiovaskularne bolezni (s prisotnima najmanj dvema kardiovaskularnima dejavnikoma tveganja), so ocenili v programu CANVAS (z integrirano analizo združenih podatkov študij CANVAS in CANVAS-R).
English: Consistent with the mechanism of sodium glucose co-transporter 2 (SGLT2) inhibition with increased UGE, vulvovaginal candidiasis in females and balanitis or balanoposthitis in males were reported in clinical studies with canagliflozin (see section 4.8).
Slovenian: V skladu z mehanizmom zaviranja prenašalca SGLT2 (sodium glucose co-transporter 2) in povečanjem izločanja glukoze z urinom so v kliničnih študijah s kanagliflozinom poročali o vulvovaginalni kandidozi pri ženskah in o balanitisu ter balanopostitisu pri moških (glejte poglavje 4.8).
English: Vokanamet should be discontinued prior to, or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable (see sections 4.2 and 4.5).
Slovenian: Zdravilo Vokanamet je treba pred slikanjem ali v času slikanja ukiniti in se ga sme ponovno uvesti najmanj 48 ur pozneje, če je bilo delovanje ledvic ponovno ovrednoteno in ocenjeno kot stabilno (glejte poglavji 4.2 in 4.5).
English: In patients with type 2 diabetes who had established cardiovascular disease or at least two risk factors for cardiovascular disease, canagliflozin was associated with an approximately 2-fold increased risk of lower limb amputation as observed in the Integrated CANVAS Program comprised of CANVAS and CANVAS-R, two large, long-term, randomised, placebo-controlled trials evaluating 10,134 patients.
Slovenian: Pri bolnikih s sladkorno boleznijo tipa 2 in z ugotovljeno srčnožilno boleznijo ali s prisotnima najmanj dvema dejavnikoma tveganja za srčnožilno bolezen je bila uporaba kanagliflozina povezana s približno dvakrat večjim tveganjem za amputacijo spodnje okončine, kar so opazili v integriranem programu CANVAS (Integrated CANVAS Program), ki je obsegal študiji CANVAS in CANVAS-R, dve veliki dolgotrajni, randomizirani, s placebom nadzorovani študiji, v katerih so ocenjevali 10.134 bolnikov.
English: Blood phosphate increased
Slovenian: , povečana koncentracija fosfata v krvi
English: Circumcision was performed at rates of 0.31 and 0.09 events per 100 patient-years on canagliflozin and placebo, respectively (see section 4.4).
Slovenian: Cirkumcizijo so izvedli s stopnjo pogostnosti 0,31 oziroma 0,09 dogodkov na 100 bolnikov-let pri uporabi kanagliflozina oziroma placeba (glejte poglavje 4.4).
English: In patients with an eGFR < 60 mL/min/1.73 m or CrCl < 60 mL/min, a higher incidence of adverse reactions associated with volume depletion (e.g., postural dizziness, orthostatic hypotension, hypotension) was reported, particularly with the 300 mg dose.
Slovenian: Pri bolnikih z eGFR < 60 ml/min/1,73 m oziroma z očistkom kreatinina < 60 ml/min so poročali o večji incidenci neželenih učinkov, povezanih s hipovolemijo (položajna omotica, ortostatska hipotenzija, hipotenzija), predvsem pri uporabi 300 mg odmerka.
English: The majority of patients with a baseline eGFR 45 mL/min/1.73 m 2 to < 60 mL/min/1.73 m 2 were on insulin and/or a sulphonylurea (85% [614/721]).
Slovenian: Večina bolnikov z izhodiščnim eGFR od 45 ml/min/1,73 m2 do < 60 ml/min/1,73 m2 je prejemala insulin in/ali sulfonilsečnino (85% [614/721]).
English: Gastrointestinal disorders very common
Slovenian: Bolezni prebavil zelo pogosti gastrointestinalni simptomi
English: Symptoms of lactic acidosis include vomiting, stomach ache, muscle cramps, a general feeling of not being well with severe tiredness, or difficulty breathing.
Slovenian: Simptomi laktacidoze vključujejo bruhanje, bolečine v trebuhu, mišične krče, splošno slabo počutje s hudo utrujenostjo ali oteženo dihanje.
English: In addition, reductions in body weight and systolic blood pressure relative to placebo were observed.
Slovenian: Poleg tega so pri bolnikih opazili zmanjšanje telesne mase in znižanje sistoličnega krvnega tlaka v primerjavi s placebom.
English: Table 7: Results from 26-week active-controlled clinical study of canagliflozin as initial combination therapy with metformin*
Slovenian: Preglednica 7: Rezultati 26-tedenske aktivne, nadzorovane študije začetnega kombiniranega zdravljenja kanagliflozina in metformina*
English: As Vokanamet contains metformin, if you take more of this medicine, you may experience lactic acidosis.
Slovenian: Če ste vzeli večji odmerek zdravila Vokanamet, kot bi smeli Ker zdravilo Vokanamet vsebuje metformin, lahko v primeru, da vzamete več tega zdravila, pride do laktacidoze.
English: Polyuria or pollakiuria includes the terms polyuria, pollakiuria, micturition urgency, nocturia, and urine output increased.
Slovenian: Izraza poliurija in polakisurija vključujeta poliurijo, polakisurijo, nenadno močno nujo po uriniranju (urgenco), nikturijo in povečano količino izločenega urina.
English: EU/1/14/918/001 (50 mg/850 mg - 20 film-coated tablets) EU/1/14/918/002 (50 mg/850 mg - 60 film-coated tablets) EU/1/14/918/003 (50 mg/850 mg - 180 film-coated tablets) EU/1/14/918/004 (50 mg/1000 mg - 20 film-coated tablets) EU/1/14/918/005 (50 mg/1000 mg - 60 film-coated tablets) EU/1/14/918/006 (50 mg/1000 mg - 180 film-coated tablets) EU/1/14/918/007 (150 mg/850 mg - 20 film-coated tablets) EU/1/14/918/008 (150 mg/850 mg - 60 film-coated tablets) EU/1/14/918/009 (150 mg/850 mg - 180 film-coated tablets) EU/1/14/918/010 (150 mg/1000 mg - 20 film-coated tablets) EU/1/14/918/011 (150 mg/1000 mg - 60 film-coated tablets) EU/1/14/918/012 (150 mg/1000 mg - 180 film-coated tablets)
Slovenian: EU/1/14/918/001 (50 mg/850 mg - 20 filmsko obloženih tablet) EU/1/14/918/002 (50 mg/850 mg - 60 filmsko obloženih tablet) EU/1/14/918/003 (50 mg/850 mg - 180 filmsko obloženih tablet) EU/1/14/918/004 (50 mg/1000 mg - 20 filmsko obloženih tablet) EU/1/14/918/005 (50 mg/1000 mg - 60 filmsko obloženih tablet) EU/1/14/918/006 (50 mg/1000 mg - 180 filmsko obloženih tablet) EU/1/14/918/007 (150 mg/850 mg - 20 filmsko obloženih tablet) EU/1/14/918/008 (150 mg/850 mg - 60 filmsko obloženih tablet) EU/1/14/918/009 (150 mg/850 mg - 180 filmsko obloženih tablet) EU/1/14/918/010 (150 mg/1000 mg - 20 filmsko obloženih tablet) EU/1/14/918/011 (150 mg/1000 mg - 60 filmsko obloženih tablet) EU/1/14/918/012 (150 mg/1000 mg - 180 filmsko obloženih tablet)
English: Based on the Kaplan-Meier plot for the first occurrence of MACE, shown below, the reduction in MACE in the canagliflozin group was observed as early as Week 26 and was maintained throughout the remainder of the study (see Figure 1).
Slovenian: Na osnovi Kaplan-Meierjeve krivulje, ki prikazuje prvi pojav pomembnega kardiovaskularnega neželenega dogodka, so zmanjšano pogostnost pojavljanja pomembnih kardiovaskularnih neželenih dogodkov v skupinah s kanagliflozinom opazili že v 26. tednu, razlika pa se je ohranila tudi v nadaljevanju študije (glejte sliko 1).
English: In a study comparing canagliflozin 300 mg once daily to sitagliptin 100 mg in triple therapy with metformin and a sulphonylurea, canagliflozin demonstrated non-inferior (p < 0.05) and superior (p < 0.05) reduction in HbA1c relative to sitagliptin.
Slovenian: V študiji, v kateri so primerjali odmerek 300 mg kanagliflozina enkrat na dan z odmerkom 100 mg sitagliptina pri trotirnem zdravljenju z metforminom in sulfonilsečnino, so dokazali neinferiornost (p < 0,05) kanagliflozina in superiorno zmanjšanje odstotka HbA1c (p < 0,05) v primerjavi s sitagliptinom.
English: Lower limb amputations (mainly of the toe and midfoot) especially in patients at high risk for heart disease
Slovenian: Kirurški in drugi medicinski posegi občasni amputacije spodnjih okončin (v glavnem prstov na nogah in dela stopala), predvsem pri bolnikih z večjim tveganjem za srčne bolezni**
English: A total of 10,134 patients were treated (4,327 in CANVAS and 5,807 in CANVAS-R; total of 4,344 randomly assigned to placebo and 5,790 to canagliflozin) and exposed for a mean of 149 weeks (exposed for a mean of 223 weeks in CANVAS and 94 weeks in CANVAS-R).
Slovenian: Skupno so zdravili 10.134 bolnikov (4.327 v študiji CANVAS in 5.807 v študiji CANVAS-R; skupaj 4.344 bolnikov z naključno dodeljenim prejemanjem placeba in 5.790 s prejemanjem kanagliflozina).
English: C]canagliflozin dose to healthy subjects, 41.5%, 7.0%, and 3.2% of the administered radioactive dose was recovered in faeces as canagliflozin, a hydroxylated metabolite, and an O-glucuronide metabolite, respectively.
Slovenian: C] označenega peroralnega odmerka kanagliflozina zdravim osebam so 41,5% danega radioaktivnega odmerka prestregli v blatu v obliki kanagliflozina, 7,0% v obliki hidroksiliranega metabolita in 3,2% v obliki O-glukuronidnega presnovka.
English: Glycaemic efficacy and safety
Slovenian: Učinkovitost in varnost pri urejanju glikemije
English: A dedicated study demonstrated that co-administration of canagliflozin 50 mg and 150 mg dosed twice daily as dual therapy with metformin produced clinically and statistically significant results relative to placebo in glycemic control, including HbA1c, the percentage of patients achieving HbA1c < 7%, change from baseline FPG, and in reductions in body weight as shown in table 5.
Slovenian: V usmerjeni študiji so dokazali, da je sočasna uporaba kanagliflozina v odmerku 50 mg oziroma 150 mg dvakrat na dan v okviru dvotirnega zdravljenja z metforminom povzročila klinično pomembne in statistično značilne rezultate nadzora glikemije v primerjavi s placebom, vključno z odstotkom bolnikov, ki so dosegli HbA1c < 7%, spremembo koncentracije glukoze na tešče od izhodiščne vrednosti in zmanjšanjem telesne mase, kot je prikazano v preglednici 5.
English: A total of 10,501 patients with type 2 diabetes participated in ten double-blind, controlled clinical efficacy and safety studies conducted to evaluate the effects of canagliflozin on glycaemic control, including 5,151 patients treated with canagliflozin in combination with metformin.
Slovenian: V desetih dvojno slepih, nadzorovanih kliničnih študijah učinkovitosti in varnosti, ki so jih izvedli za oceno učinka kanagliflozina na urejanje glikemije, je skupno sodelovalo 10.501 bolnikov s sladkorno boleznijo tipa 2, med katerimi jih je 5.151 prejemalo kanagliflozin v kombinaciji z metforminom.